Hetrombopag olamine (Herombopag; SHR-8735; trade name Hengqu), the olamine salt of Hetrombopag which is an Eltrombopag analog, is an orally bioavailable and non-peptide TPO (thrombopoietin) receptor agonist approved in June 2021 in China for the treatment of primary immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA) in adults.

纯度：≥98%

CAS：1257792-42-9